RESEARCH ARTICLE

Establishment and phenotyping of neurosphere cultures from primary neuroblastoma samples [version 1; peer review: 4 approved]

Jack Barton¹, Katherine Pacey¹, Neha Jain², Tessa Kasia¹, Darren Edwards¹, Christine Thevanesan ¹, Karin Straathof¹, Giuseppe Barone², John Anderson ^{1,2}

¹Cancer Section, DBC Programme, UCL Great Ormond Street Institute of Child Health, London, UK

²Oncology, Great Ormond Street Hospital for Children, London, UK

V1 First published: 10 Jun 2019, 8:823
<https://doi.org/10.12688/f1000research.18209.1>

Latest published: 10 Jun 2019, 8:823
<https://doi.org/10.12688/f1000research.18209.1>

Abstract

Background: Primary cell culture using serum free media supplemented with growth factors has been used in a number of cancers to propagate primary cells with stem like properties, which form as spherical cellular aggregates.

Methods: We systematically evaluated the capacity of freshly disaggregated neuroblastoma tumors to become established as neurospheres in stem cell media using a uniform protocol. 67 primary neuroblastoma samples from patients treated at a single institution were prospectively evaluated for their ability to become established in culture. Samples, either solid tissue or cells from surgical transit fluid both post chemotherapy and chemotherapy naïve, were evaluated from diagnostic needle biopsies or surgical resections.

Results: Overall 37 neurosphere cultures were successfully established from 67 samples. In 11 out of 14 cases investigated by flow cytometry, uniform staining for neuroblastoma markers CD56 and GD2 was demonstrated in CD45 negative non-hemopoietic cells, confirming neuroblastoma origin.

Conclusion: We present a simple and reproducible approach for producing primary neurospheres from neuroblastoma samples, which provides a reliable resource for future work including genetic analysis, stem cell research and models for therapeutics.

Keywords

neuroblastoma, neurosphere, stem cell

Open Peer Review

Approval Status

	1	2	3	4
version 1				
10 Jun 2019	view	view	view	view

1. **Dermot Murphy** , Royal Hospital for Sick Children, Glasgow, UK
2. **Toby Trahair** , Sydney Children's Hospital, Randwick, Australia
Lowy Cancer Research Centre, UNSW, Kensington, Australia
UNSW Medicine, NSW, Australia
3. **Juliet C. Gray**, University of Southampton, Southampton, UK
4. **Gudrun Schleiermacher** , Institut Curie, Paris, France
Institut Curie, Paris, France

Any reports and responses or comments on the article can be found at the end of the article.

This article is included in the **UCL Child Health gateway**.

This article is included in the **University College London** collection.

Corresponding author: John Anderson (j.anderson@ucl.ac.uk)

Author roles: **Barton J:** Data Curation, Writing – Original Draft Preparation; **Pacey K:** Data Curation; **Jain N:** Formal Analysis; **Kasia T:** Data Curation; **Edwards D:** Project Administration; **Thevanesan C:** Data Curation; **Straathof K:** Supervision; **Barone G:** Supervision, Writing – Review & Editing; **Anderson J:** Conceptualization, Supervision, Writing – Review & Editing

Competing interests: John Anderson hold company stock in Autolus Ltd and is a consultant for TC Biopharm

Grant information: This work was supported by the Great Ormond Street Hospital Charity [Leadership award to JA and W1134, VS0118, W1029 and W1076], GOSH NIHR Biomedical Research Centre, Research in Childhood Cancer, Great Ormond Street Hospital Histopathology Department, and the Wellcome Trust through a Clinician Scientist Fellowship.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Barton J *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Barton J, Pacey K, Jain N *et al.* **Establishment and phenotyping of neurosphere cultures from primary neuroblastoma samples [version 1; peer review: 4 approved]** F1000Research 2019, **8**:823
<https://doi.org/10.12688/f1000research.18209.1>

First published: 10 Jun 2019, **8**:823 <https://doi.org/10.12688/f1000research.18209.1>

Abbreviation	Full term
NBL	Neuroblastoma
SCM	Stem Cell Media
CNS	Central Nervous System
EGF	Epidermal Growth Factor
FGF	Fibroblast Growth Factor

Background

Neuroblastoma is the most common extra-cranial solid tumor occurring in children, and the most commonly diagnosed cancer in children under the age of 1 year¹. Tumors are thought to have embryological origin in the neural crest, arise within the sympathetic chain or adrenal gland, and are frequently metastatic². The disease is strikingly heterogeneous with a range of clinical phenotypes, from spontaneous regression, including in cases with metastases, to aggressive disease with marked resistance to radiotherapy and chemotherapy. New approaches to therapies supported by the availability of suitable tumor models that more closely resemble the human disease are essential for improving outcomes for this disease.

Established neuroblastoma cell lines have the advantage of being widely available, and enable comparison of research worldwide by their use as a common standard. However, cell lines are limited in their ability to reflect disease physiology due to adaptation to prolonged culturing conditions. Inevitable evolution and changes in transcriptional response occur during culturing, which vary between laboratories^{3,4}, and may alter diverse cell behaviors such as drug response. The potential for proliferation of subclones with greater intrinsic capacity to survive *in vitro* may lead to loss of genetic variability within a cell line compared with polyclonal cancer populations in humans.

Increasingly it is recognized that *in vivo* mouse models of tumors, established in immunodeficient animals following minimal or no *in vitro* passaging (Patient-Derived Xenografts; PDX) is a valuable tool for evaluation of therapeutic agents. Whilst many PDX models have been established by immediate surgical implantation of freshly acquired tumor surgical samples, this is not always a practical approach. Neurospheres are spherical cellular clusters derived from neural stem cells, that develop under culture conditions of serum free media supplemented with growth factors⁵. Initially produced from adult CNS tissue, they were the first demonstration of proliferative capacity in the adult brain, and have since been derived from embryonic stem cells, and CNS tumor cells. Cancer stem cells have been identified in a range of malignancies⁶, and have been implicated in initiation and progression of solid tumors⁷, and development of resistance to therapy. Growth of neurospheres in stem cell media is hypothesized to enrich for cancer stem cells. Given the importance of cancer stem cells as a potential target for treatment options, and the advantages of primary cultures over standard cell lines, it is necessary to clarify and validate methods for culturing neurospheres from primary material in neuroblastoma.

It is therefore important to investigate avenues of utilizing shorter term primary cultures such as those established in stem cell

media, based on the hypothesis that they may still remain representative of the driver genetic features of the original tumor stem cells, and have limited adaptive changes to tissue culturing conditions. Hence, we sought to establish neurosphere primary lines from neuroblastoma surgical samples, to determine the reproducibility of the technique, and to generate a resource for future research studies in therapeutics, genetics and stem cell biology. We found a high overall success rate (55%) of establishment from surgical samples.

Methods

Patients and consent

The study had ethical review board approval (REC reference 14/WM/1253 “Establishing primary cultures and cell lines from pediatric cancers”) and samples were made available following informed consent. Patients were eligible if there was a known or suspected diagnosis of neuroblastoma. All samples were included based on known or suspected diagnosis of neuroblastoma without selection on clinical criteria. In some cases with insufficient material for culture, the transport fluid used for sample transfer (0.9% saline) was placed directly into culture.

Tumor preparation

Tru-cut needle biopsies or tissue from tumor resections from neuroblastoma patients were transferred directly from operating theatre to the hospital histopathology laboratory. Following sterile cut up and routine diagnostic processing including freezing of material for research, surplus material was evaluated by a consultant pathologist for tissue viability and made available for culture. Tissue was manually disaggregated in a 10cm tissue culture dish using a sterile scalpel. Tumors that dissociated readily in this way were placed immediately into stem cell media in 25cm² flasks, 24 well plates or 12 well plates depending on the available tissue. Since it is not possible to perform an accurate cell count on the partially dissociated tumor, choice of culture container was based on estimation of size that would yield approximately 100% confluence, were the sample fully disaggregated. Where spare solid material was unavailable from a biopsy, up to 1ml of saline used to transport the sample to the histopathology laboratory was taken and added to 4ml of stem cell media in a 25cm² flask. When more than 1ml of transit fluid was provided, it was centrifuged at 300G for 5 minutes and the pellet resuspended in stem cell media. Samples that were tougher to disaggregate were digested with Accutase (ThermoFisher 00-4555-56) for up to 1 hour, or until obvious disaggregation was observed, and divided between wells of a multiwell plate based on the estimation of confluence as above.

Culture conditions

Disaggregated cells and tumor fragments were placed into standard serum free neurosphere culture media (Stem Cell Media, SCM) composed of DMEM/F12 (Sigma-Aldrich D8437), 1% B27 (Gibco 17504044) with 20ng/ml EGF (Sigma Aldrich #E9644) and 20ng/ml FGF (Fibroblast Growth Factor, Peprotech 100 – 18B) in the presence of penicillin and streptomycin antibiotics. Cells were propagated at 37°C in 5% CO₂. Cultures were inspected twice a week for cell density and presence of neurospheres, and split 1:2 to 1:5 depending on cell density and

speed of growth. Cultures were frozen in serum free DMEM/F12 media with 10% DMSO at approximately 10^7 cells per ml.

Neurosphere disaggregation and flow cytometry

A total of 14 randomly selected representative primary cultures were analyzed by flow cytometry. To produce a single cell suspension necessary for this, cells growing as a monolayer were detached with Accutase (Thermofisher) according to the manufacturer's instruction, while neurospheres were disaggregated with Accutase and the mechanical force of gentle pipetting. Surviving cells, re-suspended into single cell suspension, were stained in FACS tubes using saturating amounts (1–5ul of stock) of antibody in 100ul PBS using the following panel of directly conjugated monoclonal antibodies all from Biolegend: GD2-PE (357304, RRID: [AB_2561885](#)), CD56-APC/Cy7 (318332, RRID: [AB_10896424](#)), CD45-BV711 (304049, RRID: [AB_2563465](#)) controlled for nonspecific staining using isotype-matched labelled polyclonal antibodies. The stained primary culture cells were incubated on ice with antibody mix for 30 minutes and then washed with PBS and centrifuged at 300G for 5 minutes. Data was collected with the BD LSRII flow cytometer (BD Biosciences) and data analysis used [FlowJo](#) software (v8.8.3).

The gating strategy excluded dead cells by a live/dead stain using DAPI. To exclude leukocytes that may be present from blood in the original sample, the resulting live population was gated on CD45 negative and CD56 positive cells, the latter a standard marker for neuroblastoma. This gated cell population of CD45-ve/CD56+ve cells was then examined for expression of GD2, also ubiquitously expressed on neuroblastoma.

Statistical analysis

Chi-squared tests were used to determine significance of association of categorical variables; for example successful versus non successful expansion correlated with pre versus post chemotherapy. Data were tabulated and tests of significance were performed using Microsoft Excel 2016 and [GraphPad Prism](#) v6.0

Results

Neurosphere cultures can be established from the majority of neuroblastoma patient samples grown in suspension cultures and retain typical neuroblastoma surface immunophenotype

Between October 2014 to end of 2016, tumor biopsies or resections of 67 consecutive neuroblastoma samples from 52 patients treated at Great Ormond Street Hospital London were systematically evaluated for their ability to establish primary neurosphere lines. Of these, 39 were primary needle biopsies and 28 were surgical resections of which 24 were post chemotherapy resections and 4 were primary (treatment-naïve) resections.

The success in terms of establishment of cultures was determined by the ability of cultures to produce discrete visible neurospheres. All cultures derived from neuroblastoma samples were observed to grow as a mixture of phenotypes including neurospheres, single suspension cells, and as monolayer, although often one of the three growth patterns was predominant. Cases could be dichotomized into those that formed

spheres within the first 14 days of establishment and then went on to form long term successful cultures, and those that never formed spheres and were classified as “unsuccessful cultures”. The overall success rate, as thus defined, was 55%. It appeared that successful establishment of neurospheres could be made from chemotherapy-naïve primary tumors and post chemotherapy surgical samples, as well as primary needle biopsies. Successful establishment of lines is summarized in [Table 1](#). Of 43 chemotherapy-naïve samples (39 biopsies and 4 surgical excisions), 29 (67%) were successfully established, whereas for the post-chemotherapy surgical samples success rate was 8 out of 24 (33%), which is significantly inferior (Chi Sq $p < 0.008$) (see underlying data⁸). This suggests that the protocol, if applied to optimally procured tissue, would have a success rate over 65%.

Due to the impossibility of counting cells both at the start of culturing and following establishment of spheres, it is not possible to plot growth curves. However, the range of time from initial seeding to establishment of a confluent 75cm² flask is approximately 2 to 10 weeks showing the marked heterogeneity of growth rates.

In order to determine that these were neuroblastoma cells, 14 representative samples were analyzed by flow cytometry. Cells from primary cultures were assessed for expression of the pan leucocyte marker CD45, which neuroblastoma cells do not express, and for ubiquitously expressed NBL markers CD56 and GD2. Of the samples tested, 79% exhibited this characteristic neuroblastoma staining pattern. We found that the neurosphere cultures showed a very bright and homogeneous staining for both NBL markers ([Figure 1](#))

Neurosphere cultures can be successfully established from transit fluid samples and retain typical neuroblastoma immunophenotype

We were interested in whether it is possible to establish neuroblastoma lines when using very small amounts of tissue. In cases with insufficient tissue to culture, 1ml of transportation fluid was put directly into 4ml stem cell media (SCM) in a 25cm²

Table 1. Establishment of sphere cultures from primary sample type. Of the chemotherapy-naïve surgical excisions, 2 of these 4 were from recurrences.

	Samples	Sphere cultures (%)
Total samples	67	37 (55)
Total fluid only samples	17	9 (53)
Total solid samples	50	28 (56)
Total biopsy samples	39	25 (64)
Diagnostic biopsies	34	21 (62)
Recurrence biopsies	5	4 (80)
Biopsy fluid only cultures	15	9 (60)
Total excision samples	28	12 (43)
Post chemotherapy	24	8 (33)
Chemotherapy naïve	4	4 (100)

Figure 1. Neurospheres derived from neuroblastoma primary tumors retain typical immunophenotype. **A)** representative flow cytometric staining for two independent cultures (excision culture 3544 (upper) and biopsy culture 4669 (lower) following gating on live cells. **B)** graphical representation of the staining pattern in 14 evaluated samples; positivity was categorized into dim, medium and bright based on MFI and scored as 1, 2 and 3 respectively.

tissue culture flask, testing the hypothesis that small amounts of residual tumor cells within the transport media would be able to establish. Where transport fluid provided was more than 1ml, this was centrifuged and the pellet resuspended in SCM. Cultures established from transit fluid had a comparable success rate to those established from solid tissue samples (9 out of 15= 55% versus 25 out of 39 =64% for biopsies; Chi Sq p=0.78).

To perform a further unbiased comparison, eight patients had neurospheres cultured from the same biopsy with separate culturing of the solid tissue and surgical transit fluid. In three there was no successful growth, in three there was concordance of growth from the two sources, and in two there was success from solid tissue but not transit fluid; there were no cases with success of transit fluid but failure from solid tissue. Therefore transit fluid appears a less reliable source of material but a useful adjunct in the context of scarce material.

Heterogeneity of *in vitro* growth phenotype and adaptation to growth on laminin

In addition to growth as neurospheres, primary cultures established in SCM were observed to grow as adherent monolayers, single cell suspensions, or mixtures of all three growth patterns. Moreover, there is marked heterogeneity in the size of neurospheres both within and between samples. It is not possible to quantify this heterogeneity, but all the NBL SCM lines contained some elements of adherent, single cell suspension and neurospheres. SCM derived from gliomas can be grown as adherent cultures by coating culture flasks with laminin and so we were interested in whether neuroblastoma primary cultures could also adopt this phenotype. We did not attempt initial establishment in laminin in any cases. In our hands, when established or establishing SCM lines were transferred to laminin, the degree of attachment increased markedly, with outgrowth of adherent spheres and associated adherent cells growing out as a

monolayer. In some cases where growth in suspension appeared slow, the change to laminin appeared to accelerate growth. Because of the impossibility of counting cells in neurospheres without majorly disrupting them, it was not possible to quantify these aspects of altered growth in laminin. On return of laminin cultured cells to non-coated flasks, they reverted to predominant suspension growth pattern.

No significant association between success rate with clinical/histological features

Patient characteristics and ability to establish neurospheres is shown in Table 2. The number of male samples were 37 out of 67. The ability to establish neurospheres did not vary depending on gender (59% vs 50%). Biopsies which demonstrated only undifferentiated neuroblastoma had a higher but non-significant success rate in establishing neurospheres than those which showed any evidence of differentiation or post chemotherapy changes (60% vs 45%). Age, stage, MYCN amplification and the presence of segmental chromosomal aberrations were all non significant in terms of neurosphere success rate (Table 2).

Six patients had two samples collected at different time points during treatment. For four of them there was no concordance

for success between the timepoints whereas two patients (one success and one failure) the different timepoints were concordant. Therefore we failed to find any evidence that patient-specific factors govern success rate.

Discussion

Here we present data from a series of 67 samples diagnosed with neuroblastoma, from which tumor tissue or surgical transit fluid was obtained and used to culture tumor spheres under conditions commonly used in the culture of neural stem cells⁶. Tumor spheres were subsequently dissociated and assessed by flow cytometry for presence of neuroblastoma markers GD2 and CD56, to show that cells and tumor spheres grown in culture retain the characteristic markers the cells of their tissue of origin. These cells may then be used as targets *in vitro* for drug development, or for engraftment *in vivo* for the development of patient-derived xenograft models that better reflect the heterogeneity of this disease.

Although well established that it is possible to use SCM to propagate stem cells in the form of neurospheres from a number of different cancer types⁹, the literature is sparse in regards to their evaluation in neuroblastoma. We have therefore systematically evaluated success rate and shown that with simple culturing techniques it is possible to establish primary lines which retain the characteristic immunophenotypic features of neuroblastic tumors. Further studies will be required to establish the success rate of formation of tumors, for example in xenograft models. Moreover, it will be interesting to study the ability of these cells to differentiate into neuroblasts *in vitro*, for example by transfer to normal growth media with serum, as well as the mutational drift compared to the original tumor if any.

It would be advantageous to have a method of establishment of primary cell culture which reproducibly leads to cell expansion. Even if the expanded cells represent a subclone that are adapted to *in vitro* conditions (for example cancer stem cell expansion in stem cell media), this still represents an advantage over methods such as establishment of cell lines in normal growth media with serum, that typically go through a crisis phase before establishment of an emergent line that is presumably highly evolved for adaptation to tissue culture conditions, and therefore less likely to represent the *in vivo* tumor. Conventional two-dimensional monolayer models have been useful in understanding many of the characteristics of neuroblastoma cell biology, but in addition to the concerns about genetic evolution to adapt to typical cell culture conditions, they do not accurately reflect the multicellular physiology of tumors *in vivo* or how the tumor microenvironment is developed. Neither adherent monolayer cultures nor neurospheres are physiological, and occur only during *in vitro* culturing conditions, however the latter may offer some advantages as a research tool. Although neurospheres do not have the architecture and vasculature of *in vivo* tumors, their three-dimensional structure may have advantages of cell monolayers in terms of better representing aspects of three-dimensional tumors such as central hypoxia and drug penetrance. Future studies on neurosphere permeability and response to therapeutics might be of interest to evaluate their role as an *in vitro* tumor model.

Table 2. Patient features and correlation with establishment of spheres. There were no significant associations with neurosphere establishment (Chi-square). L1, L2, M or MS stage disease at diagnosis used the International Neuroblastoma Risk Group (INRG) Classification System.

	Number (%)	Successful Establishment of spheres (%)
Gender		
Male	37 (55)	22 (59)
Female	30 (45)	15 (50)
Age		
≤18months	36 (54)	23 (64)
>18months	31 (46)	14 (45)
INRG Stage at Diagnosis		
L1	3 (4)	2 (67)
L2	21 (31)	14 (67)
M	39 (58)	18 (46)
MS	4 (6)	3 (75)
NMYC Amplification		
Yes	17 (25)	7 (41)
No	50 (75)	30 (60)
Segmental Chromosomal Abnormalities		
Yes	21 (31)	14 (67)
No	46 (69)	23 (50)
Tumor Biology		
Undifferentiated	47 (70)	28 (60)
Differentiating	20 (30)	9 (45)

The establishment of neurospheres comprised of primary neural stem cells has also been frequently used and there exist a variety of methods for their establishment⁶. However, the sphere culture model is limited by its sensitivity to culture technique including sensitivity to alterations in media or cell density, or frequent passaging and dissociation^{5,10}. In our hands the neuroblastoma SCM cultures do show this sensitivity to changes in environmental conditions but retain the capacity to recover from stress if left alone in normal SCM growth conditions. Due to the long-term nature of their propagation, meticulous attention to sterility is needed to prevent the outbreak of microbial contamination.

While neurospheres represent a straightforward approach for maintaining cancer cells in culture, and whilst they are a potentially useful tool for cancer stem cell investigations, further studies are needed to determine how useful they will be in developing biological or therapeutics models for basic or translational research. Our demonstration of high success rate of their establishment using a uniformly applied protocol is a valuable contribution to the field for identifying an alternate and reproducible approach to expanding the reagents available for neuroblastoma research.

Ethics approval and consent to participate

The study had ethical review board approval (REC reference 14/WM/1253 “Establishing primary cultures and cell lines from pediatric cancers”) and all patient samples were collected with written full consent

Data availability

Underlying data

Open Science Framework: Primary neuroblastoma cultures database. <https://doi.org/10.17605/OSF.IO/T2RFB>⁸

This project contains the following underlying data:

- FACS data (folder containing output FACS files for different cases)
- Flow Cases - reference table.docx (Reference table for FACS output files)
- Full data sheet no identifiers.xlsx (spreadsheet of sample characteristics)

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](#) (CC-BY 4.0).

Grant information

This work was supported by the Great Ormond Street Hospital Charity [Leadership award to JA and W1134, VS0118, W1029 and W1076], GOSH NIHR Biomedical Research Centre, Research in Childhood Cancer, Great Ormond Street Hospital Histopathology Department, and the Wellcome Trust through a Clinician Scientist Fellowship.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Maris JM: **Recent advances in neuroblastoma**. *N Engl J Med*. 2010; **362**(23): 2202–2211.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Marshall GM, Carter DR, Cheung BB, *et al.*: **The prenatal origins of cancer**. *Nat Rev Cancer*. 2014; **14**(4): 277–289.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Ben-David U, Siranosian B, Ha G, *et al.*: **Genetic and transcriptional evolution alters cancer cell line drug response**. *Nature*. 2018; **560**(7718): 325–330.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Pan C, Kumar C, Bohl S, *et al.*: **Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions**. *Mol Cell Proteomics*. 2009; **8**(3): 443–450.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Jensen JB, Parmar M: **Strengths and limitations of the neurosphere culture system**. *Mol Neurobiol*. 2006; **34**(3): 153–161.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Clarke MF, Hass AT: **Cancer Stem Cells** - Clarke - - Major Reference Works - Wiley Online Library. Accessed October 26, 2018.
[Publisher Full Text](#)
7. Visvader JE, Lindeman GJ: **Cancer stem cells in solid tumours: accumulating evidence and unresolved questions**. *Nat Rev Cancer*. 2008; **8**(10): 755–768.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. ANDERSON J: **Primary neuroblastoma cultures database**. 2019.
<http://www.doi.org/10.17605/OSF.IO/T2RFB>
9. Singh SK, Clarke ID, Terasaki M, *et al.*: **Identification of a cancer stem cell in human brain tumors**. *Cancer Res*. 2003; **63**(18): 5821–5828.
[PubMed Abstract](#)
10. Singec I, Knoth R, Meyer RP, *et al.*: **Defining the actual sensitivity and specificity of the neurosphere assay in stem cell biology**. *Nat Methods*. 2006; **3**(10): 801–806.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 08 July 2019

<https://doi.org/10.5256/f1000research.19917.r49684>

© 2019 Schleiermacher G. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gudrun Schleiermacher

¹ SIREDO Department of Pediatric Oncology, Institut Curie, Paris, France

² INSERM U830, RTOP (Recherche Translationnelle en Oncologie Pédiatrique), Institut Curie, Paris, France

Neuroblastoma is a clinically and genetically heterogeneous pediatric tumor. Precise biological and molecular characterization of tumor cells is increasingly becoming an integral part of patient care, with treatment stratification depending not only on clinical, but also on molecular characteristics. However, tumor samples are frequently small, especially when obtained by fine needle biopsies, with frequently only a limited amount of biological material available for increasingly complex molecular investigations or cellular screening procedures.

In this manuscript, the authors describe the technical aspects of direct culture of neuroblastoma samples for the establishment of neurosphere cultures. Importantly, they describe a procedure which is applied to consecutive cases in a single center, with samples obtained by different techniques (surgical resections, fine needle biopsies, transport fluid) and at different time points (at diagnosis, post chemotherapy). The success rate is 55% (37/67 samples), without any significant association between the success rate of establishing a neurosphere culture and clinical/histological/genetic features. Characterization of the obtained neurosphere cultures is still limited, but the results indicate that the cultured cells do express neuroblastoma markers.

The ultimate usefulness of the established neurosphere cultures will depend on a number of aspects. It will be necessary to compare genetic/epigenetic/cell identity features between the primary tumor and corresponding neurosphere culture, to search more in detail for features linked to culture success rates and to establish the duration of tumor growth.

The importance of this work is linked to the presentation of a reproducible method for the expansion of frequently rare tumor tissue, enabling more large scale use of such samples for molecular characterization, drug screening and other applications for the patients' benefit.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Pediatric oncologist (physician-scientist); translational research focusing on genetic analyses of neuroblastoma and other high risk pediatric cancers

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 02 July 2019

<https://doi.org/10.5256/f1000research.19917.r49683>

© 2019 Gray J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Juliet C. Gray

Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, Department of Paediatric Oncology, University of Southampton, Southampton, UK

Neuroblastoma is a rare paediatric tumour which accounts for a disproportionately high number of paediatric cancer deaths. Fresh tissue samples are usually small and scarce, and established cell lines are likely to poorly represent the heterogenous nature of the disease. This paper describes a simple methodology for establishing neurosphere cultures from small samples of fresh biopsy tissue, with a relatively high success rate. This is a potentially very useful technique for extending the use of limited primary tissue samples to maximal benefit. Of note, success was even achieved with fluid from around surgical/biopsy samples, rather than solid tissue samples, which is potentially very useful when sample size is limited.

The article is clearly written and will be of interest to those working in the field.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Neuroblastoma

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 01 July 2019

<https://doi.org/10.5256/f1000research.19917.r49685>

© 2019 Trahair T. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Toby Trahair

¹ Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia

² Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Kensington, NSW, Australia

³ School of Women's and Children's Health, UNSW Medicine, NSW, Australia

This is a straightforward technical report on direct culture of neuroblastoma samples from consecutive cases treated at Great Ormond Street.

The research team has taken a logical approach to establishing an easy method to establish patient-derived neurospheres. Tumour samples were derived from a number of sources (open biopsy, needle biopsy & from transport fluid). The overall success rate (37 cultures from 67

samples) confirms that this approach is feasible.

The characterisation of the resulting neurosphere cultures has been limited, but expression of both CD56 and GD2 suggests that the cultures really are neuroblastic tumours.

The significance of this work really lies in the downstream application of patient-derived cultures. There are a number of unanswered questions, specifically how representative the neurosphere cultures are of the donor tumour, whether there is any correlation between the capacity to establish a culture and patient outcome, whether the neurosphere models can be propagated as xenografts, and if it is possible to derive neurosphere cultures from each genetic/genomic subtype of neuroblastoma (e.g. MYCN amplified, TERT rearranged, ATRX deleted, etc.).

Overall, with an increasing focus on personalisation of therapy, whilst a simple piece of work, I believe it is a valuable contribution to the field and will be helpful for other groups engaged in such work.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Paediatric Haematologist & Oncologist, translational research in neuroblastoma & personalised medicine

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 01 July 2019

<https://doi.org/10.5256/f1000research.19917.r49686>

© 2019 Murphy D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Dermot Murphy

Department of Oncology, Royal Hospital for Sick Children, Glasgow, UK

The article is scientifically sound. My only criticism is stylistic. I think the sentences are too long and the punctuation could be better. The text is clunky.

- For example:

“The disease is strikingly heterogeneous with a range of clinical phenotypes, from spontaneous regression, including in cases with metastases, to aggressive disease with marked resistance to radiotherapy and chemotherapy. New approaches to therapies supported by the availability of suitable tumor models that more closely resemble the human disease are essential for improving outcomes for this disease.”

- Edit to:

Neuroblastoma is strikingly heterogeneous. Clinical phenotypes range from spontaneous regression to aggressive disease characterised by marked resistance to radio and chemotherapy. New therapeutic approaches, supported by tumor models more closely resembling human disease, are essential for improving outcomes in children.

There are many more examples in the subsequent manuscript. Tight editing would vastly improve readability.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Neuroblastoma and children's cancer in general. Palliative care, statistics.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research